

## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

1-30 (Cancelled)

31 (Currently amended): A method for modulating an immune response comprising administering to a human a purified compound selected from the group consisting of an antibody, an alpha (2) macroglobulin fragment, an alpha (2) macroglobulin receptor fragment, and a heat shock protein fragment, which compound interferes with the interaction of a first heat shock protein with the alpha (2) macroglobulin receptor, and is in an amount effective to modulate the immune response of said human, ~~wherein the compound is other than a heat shock protein, RAP, alpha (2) macroglobulin, a complex of a heat shock protein and a peptide, or a complex of alpha (2) macroglobulin and a peptide.~~

32-70 (Cancelled)

71 (Currently amended): A method for inhibiting an immune response comprising administering to a human a purified compound selected from the group consisting of an antibody, an alpha (2) macroglobulin fragment, and a heat shock protein fragment which compound binds to the alpha (2) macroglobulin receptor, in an amount effective to inhibit the immune response of said human, ~~wherein the compound is other than a heat shock protein, RAP, alpha (2) macroglobulin, a complex of a heat shock protein and a peptide, or a complex of alpha (2) macroglobulin and a peptide.~~

72-75 (Cancelled)

76 (Previously presented): The method of claim 31 or 71 wherein the compound is an antagonist which decreases alpha (2) macroglobulin receptor activity.

77 (Previously presented): The method of claim 31 wherein the compound is an antibody specific for alpha (2) macroglobulin.

78 (Previously presented): The method of claim 31 or 71 wherein the compound is an antibody specific for alpha (2) macroglobulin receptor.

79 (Currently amended): The method of claim 31 wherein the compound is an antibody specific for the first heat shock protein.

80 (Previously presented): The method of claim 31, wherein the first heat shock protein is gp96.

81 (Previously presented): The method of claim 31 wherein the first heat shock protein is Hsp70.

82 (Previously presented): The method of claim 31 wherein the first heat shock protein is Hsp90.

83 (Canceled)

84 (Previously presented): The method of claim 31 or 71 wherein the compound is a peptide.

85 (Previously presented): The method of claim 31 wherein the immune response is to an autoimmune antigen.

86 (Previously presented): The method of claim 31 wherein the immune response is to an infectious disease antigen.

87 (Currently amended): The method of claim 31 wherein the immune response is to ~~an~~ a proliferative cell disorder other than cancer.

88 (Previously presented): The method of claim 31 wherein the immune response is to a cancer antigen.

89 (Previously presented): The method of claim 88, wherein the cancer is a fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma,

neuroblastoma, retinoblastoma, leukemias, polycythemia vera, lymphoma, multiple myeloma, Waldenström's macroglobulinemia, or heavy chain disease.

90 (Previously presented): The method of claim 86, wherein the infectious disease is caused by a infectious agent that is a hepatitis type B virus, adeno-associated virus, cytomegalovirus, papilloma virus, polyoma viruses, SV40, adenoviruses, herpes simplex type I, herpes simplex type II, Epstein-Barr virus, poxviruses, variola vaccinia virus, RNA viruses, human immunodeficiency virus type I, human immunodeficiency virus type II, human T-cell lymphotropic virus type I, human T-cell lymphotropic virus type II, influenza virus, measles virus, rabies virus, Sendai virus, poliomyelitis virus, coxsackieviruses, rhinoviruses, reoviruses, rubella virus, Semliki forest virus, arboviruses, hepatitis type A virus, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter fetus*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Salmonella typhi*, *Treponema pallidum*, *Treponema pertenue*, *Treponema carateneum*, *Borrelia vincentii*, *Borrelia burgdorferi*, *Leptospira icterohemorrhagiae*, *Mycobacterium tuberculosis*, *Toxoplasma gondii*, *Pneumocystis carinii*, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella melitensis*, *Mycoplasma spp.*, *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia spp.*, *Helicobacter pylori*, *Entamoeba histolytica*, *Trichomonas tenax*, *Trichomonas hominis*, *Trichomonas vaginalis*, *Trypanosoma gambiense*, *Trypanosoma rhodesiense*, *Trypanosoma cruzi*, *Leishmania donovani*, *Leishmania tropica*, *Leishmania braziliensis*, *Pneumocystis pneumonia*, *Plasmodium vivax*, *Plasmodium falciparum*, or *Plasmodium malaria*.

91 (Previously presented): The method of claim 85, wherein the autoimmune antigen is of: insulin dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, pernicious anemia, autoimmune thyroiditis, idiopathic Addison's disease, vitiligo, gluten-sensitive enteropathy, Graves' disease, myasthenia gravis, autoimmune neutropenia, idiopathic thrombocytopenia purpura,

rheumatoid arthritis, cirrhosis, pemphigus vulgaris, autoimmune infertility, Goodpasture's disease, bullous pemphigoid, discoid lupus, ulcerative colitis, or dense deposit disease.

92 (Previously presented): The method of claim 31 or 71 wherein the compound comprises a polyclonal antibody, monoclonal antibody, humanized antibody, chimeric antibody, single chain antibody, Fab fragment, F(ab')<sub>2</sub> fragment, fragment produced by a Fab expression library, or anti-idiotypic antibody.

93 (Previously presented): The method of claim 31 or 71 wherein the compound comprises an epitope-binding fragment of a polyclonal antibody, monoclonal antibody, humanized antibody, chimeric antibody, single chain antibody, Fab fragment, F(ab')<sub>2</sub> fragment, fragment produced by a Fab expression library, or anti-idiotypic antibody.